Total Payments
$53,680
2024 Payments
$7,941
Companies
26
Transactions
110
Medicare Patients
5,341
Medicare Billing
$4.6M
Payment Breakdown by Category
Other$40,357 (75.2%)
Travel$4,837 (9.0%)
Consulting$4,624 (8.6%)
Food & Beverage$3,720 (6.9%)
Education$142.23 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,357 | 14 | 75.2% |
| Travel and Lodging | $4,837 | 8 | 9.0% |
| Consulting Fee | $4,624 | 3 | 8.6% |
| Food and Beverage | $3,720 | 81 | 6.9% |
| Education | $142.23 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $45,800 | 34 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,244 | 2 | $0 (2020) |
| AbbVie Inc. | $1,826 | 3 | $0 (2020) |
| Rigel Pharmaceuticals, Inc. | $1,324 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $316.53 | 8 | $0 (2021) |
| BeiGene USA, Inc. | $294.43 | 4 | $0 (2023) |
| Incyte Corporation | $247.75 | 2 | $0 (2022) |
| GENZYME CORPORATION | $234.72 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $217.28 | 13 | $0 (2022) |
| TG THERAPEUTICS, INC. | $217.10 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,941 | 8 | Regeneron Healthcare Solutions, Inc. ($7,785) |
| 2023 | $37,280 | 31 | Regeneron Healthcare Solutions, Inc. ($36,907) |
| 2022 | $1,330 | 6 | Regeneron Healthcare Solutions, Inc. ($1,108) |
| 2021 | $784.60 | 13 | TG THERAPEUTICS, INC. ($217.10) |
| 2020 | $5,548 | 13 | AstraZeneca Pharmaceuticals LP ($2,220) |
| 2019 | $722.78 | 33 | E.R. Squibb & Sons, L.L.C. ($161.56) |
| 2018 | $36.53 | 3 | Genentech USA, Inc. ($25.15) |
| 2017 | $37.37 | 3 | Pharmacyclics LLC, An AbbVie Company ($22.40) |
All Payment Transactions
110 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $120.41 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $91.41 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $31.60 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,684.00 | General |
| Category: ONCOLOGY | ||||||
| 03/29/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $61.06 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $123.99 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 02/27/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,684.00 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $144.10 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,807.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $44.26 | General |
| 11/11/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $972.36 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $136.24 | General |
| Category: Oncology | ||||||
| 10/03/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $258.73 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $50.60 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $6.18 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,807.00 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $325.04 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $123.75 | General |
| Category: ONCOLOGY | ||||||
| 08/24/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,961.00 | General |
| Category: ONCOLOGY | ||||||
| 07/05/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $563.00 | General |
| Category: ONCOLOGY | ||||||
| 05/19/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $604.00 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,807.00 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 49 | 1,761 | 139,501 | $14.5M | $1.9M |
| 2022 | 38 | 1,348 | 79,905 | $7.2M | $906,789 |
| 2021 | 30 | 994 | 58,865 | $4.5M | $686,568 |
| 2020 | 32 | 1,238 | 111,292 | $7.4M | $1.1M |
Total Patients
5,341
Total Services
389,563
Medicare Billing
$4.6M
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 24 | 21,601 | $5.6M | $934,087 | 16.8% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 12,600 | $1.8M | $298,434 | 16.8% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 12 | 4,900 | $1.4M | $174,649 | 12.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 29 | 48,100 | $1.3M | $113,456 | 8.5% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 18 | 900 | $1.7M | $71,273 | 4.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 225 | 636 | $266,484 | $57,719 | 21.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 2,940 | $240,960 | $54,292 | 22.5% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 17 | 2,600 | $254,954 | $43,339 | 17.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 101 | 430 | $273,910 | $40,689 | 14.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 165 | $97,515 | $20,719 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 150 | 276 | $75,072 | $16,668 | 22.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 13 | 78 | $520,642 | $10,500 | 2.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 70 | 176 | $73,568 | $8,110 | 11.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $33,841 | $6,888 | 20.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 33 | 126 | $70,560 | $5,867 | 8.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 65 | 506 | $115,368 | $5,720 | 5.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 94 | 486 | $76,788 | $4,976 | 6.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 45 | 206 | $79,104 | $4,307 | 5.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 24 | 138 | $76,452 | $2,818 | 3.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 51 | $28,509 | $2,662 | 9.3% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 16 | 15,800 | $29,879 | $2,559 | 8.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 31 | 86 | $22,360 | $2,296 | 10.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $10,854 | $2,258 | 20.8% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 13 | 43 | $22,618 | $1,746 | 7.7% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 17 | 11,550 | $93,324 | $1,392 | 1.5% |
About Dr. Vivek Abhyankar, MD
Dr. Vivek Abhyankar, MD is a Hematology & Oncology healthcare provider based in Marietta, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1083607089.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vivek Abhyankar, MD has received a total of $53,680 in payments from pharmaceutical and medical device companies, with $7,941 received in 2024. These payments were reported across 110 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($40,357).
As a Medicare-enrolled provider, Abhyankar has provided services to 5,341 Medicare beneficiaries, totaling 389,563 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Marietta, OH
- Active Since 08/24/2005
- Last Updated 08/16/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1083607089
Products in Payments
- LIBTAYO (Biological) $45,800
- VENCLEXTA (Drug) $1,800
- Tavalisse (Drug) $1,200
- OPDIVO (Biological) $305.04
- BRUKINSA (Drug) $294.43
- SARCLISA (Biological) $234.72
- UKONIQ (Drug) $217.10
- KISQALI (Drug) $171.05
- PEMAZYRE (Drug) $124.62
- Rezlidhia (Drug) $123.99
- MONJUVI (Drug) $123.13
- Imbruvica (Drug) $114.61
- FOUNDATIONONE (Device) $71.70
- GAZYVA (Biological) $61.74
- Neulasta (Biological) $61.36
- Inrebic (Drug) $39.45
- Kyprolis (Drug) $37.55
- VONJO (Drug) $31.60
- VENCLEXTA (Biological) $30.94
- IMBRUVICA (Drug) $28.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Marietta
Dr. Steven Mccune, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $492,856
Hematology & Oncology $492,856
Dr. Gena Volas-Redd, Md, MD
Hematology & Oncology — Payments: $115,709
Hematology & Oncology $115,709
Dr. John French, Md, MD
Hematology & Oncology — Payments: $70,611
Hematology & Oncology $70,611
Dr. Louis Garrot, M.d, M.D
Hematology & Oncology — Payments: $57,738
Hematology & Oncology $57,738
Dr. Dean Kirkel, Md, MD
Hematology & Oncology — Payments: $53,593
Hematology & Oncology $53,593
Dr. Bruce Gould, Md, MD
Hematology & Oncology — Payments: $41,448
Hematology & Oncology $41,448